These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 19641319)

  • 1. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
    Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
    Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
    Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
    Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
    Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
    Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer disease assessment scale-cognitive subscale.
    Pyo G; Elble RJ; Ala T; Markwell SJ
    Alzheimer Dis Assoc Disord; 2006; 20(1):16-22. PubMed ID: 16493231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population.
    Hannesdóttir K; Snaedal J
    Nord J Psychiatry; 2002; 56(3):201-6. PubMed ID: 12079572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores.
    Balsis S; Unger AA; Benge JF; Geraci L; Doody RS
    Alzheimers Dement; 2012 Jul; 8(4):288-94. PubMed ID: 22465173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
    Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
    Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS Study.
    Ylikoski R; Jokinen H; Andersen P; Salonen O; Madureira S; Ferro J; Barkhof F; van der Flier W; Schmidt R; Fazekas F; Scheltens P; Waldemar G; Salvadori E; Pantoni L; Inzitari D; Erkinjuntti T;
    Dement Geriatr Cogn Disord; 2007; 24(2):73-81. PubMed ID: 17565216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls.
    Graham DP; Cully JA; Snow AL; Massman P; Doody R
    Alzheimer Dis Assoc Disord; 2004; 18(4):236-40. PubMed ID: 15592137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A neuropsychological test battery for use in Alzheimer disease clinical trials.
    Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
    Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of Alzheimer disease assessment scale-cognitive part in predicting progress for amnestic mild cognitive impairment to Alzheimer disease.
    Rozzini L; Vicini Chilovi B; Bertoletti E; Conti M; Delrio I; Trabucchi M; Padovani A
    J Geriatr Psychiatry Neurol; 2008 Dec; 21(4):261-7. PubMed ID: 19017783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memory, language, and praxis in Alzheimer's disease: norms for outpatient clinical trial populations.
    Doraiswamy PM; Bieber F; Kaiser L; Connors K; Krishnan KR; Reuning-Scherer J; Gulanski B
    Psychopharmacol Bull; 1997; 33(1):123-8. PubMed ID: 9133763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the German revised Addenbrooke's cognitive examination for detecting mild cognitive impairment, mild dementia in alzheimer's disease and frontotemporal lobar degeneration.
    Alexopoulos P; Ebert A; Richter-Schmidinger T; Schöll E; Natale B; Aguilar CA; Gourzis P; Weih M; Perneczky R; Diehl-Schmid J; Kneib T; Förstl H; Kurz A; Danek A; Kornhuber J
    Dement Geriatr Cogn Disord; 2010; 29(5):448-56. PubMed ID: 20502019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients.
    Talwalker S
    J Biopharm Stat; 1996 Nov; 6(4):443-56. PubMed ID: 8969979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of mild cognitive impairment in Chinese older adults--a multistage validation of the Chinese abbreviated mild cognitive impairment test.
    Lam LC; Tam CW; Lui VW; Chan WC; Chan SS; Chiu HF; Leung T; Tham MK; Ho KS; Chan WM
    Neuroepidemiology; 2008; 30(1):6-12. PubMed ID: 18204291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues.
    Perneczky R; Pohl C; Sorg C; Hartmann J; Komossa K; Alexopoulos P; Wagenpfeil S; Kurz A
    Age Ageing; 2006 May; 35(3):240-5. PubMed ID: 16513677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Validity of the Japanese version of Rivermead Behavioural Memory Test for evaluation of everyday memory function in patients with mild Alzheimer's disease].
    Matsuda A; Kazui H; Hirono N; Mori E
    No To Shinkei; 2002 Aug; 54(8):673-8. PubMed ID: 12355878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.